Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 331.73 Million EUR | 17.92% |
| 2022 | 281.3 Million EUR | 62.28% |
| 2021 | 173.35 Million EUR | 25.84% |
| 2020 | 137.75 Million EUR | 461.54% |
| 2019 | 24.53 Million EUR | 202.74% |
| 2018 | 8.1 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 91.29 Million EUR | 10.72% |
| 2024 Q2 | 90.99 Million EUR | -0.34% |
| 2024 Q3 | 87.64 Million EUR | -3.68% |
| 2023 Q4 | 82.45 Million EUR | 3.23% |
| 2023 Q2 | 81.31 Million EUR | -7.69% |
| 2023 Q3 | 79.87 Million EUR | -1.76% |
| 2023 Q1 | 88.08 Million EUR | 16.74% |
| 2023 FY | 331.73 Million EUR | 17.92% |
| 2022 Q4 | 75.45 Million EUR | 6.45% |
| 2022 FY | 281.3 Million EUR | 62.28% |
| 2022 Q3 | 70.88 Million EUR | 5.75% |
| 2022 Q2 | 67.02 Million EUR | -1.34% |
| 2022 Q1 | 67.94 Million EUR | 39.51% |
| 2021 Q2 | 39.43 Million EUR | -9.99% |
| 2021 FY | 173.35 Million EUR | 25.84% |
| 2021 Q4 | 48.7 Million EUR | 17.39% |
| 2021 Q3 | 41.48 Million EUR | 5.19% |
| 2021 Q1 | 43.81 Million EUR | -53.61% |
| 2020 Q1 | 10.52 Million EUR | 0.0% |
| 2020 Q3 | 20.79 Million EUR | 73.69% |
| 2020 Q2 | 11.97 Million EUR | 13.78% |
| 2020 Q4 | 94.45 Million EUR | 354.12% |
| 2020 FY | 137.75 Million EUR | 461.54% |
| 2019 FY | 24.53 Million EUR | 202.74% |
| 2018 FY | 8.1 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AroCell AB (publ) | 43.03 Million SEK | -670.766% |
| Devyser Diagnostics AB (publ) | 169.3 Million SEK | -95.942% |
| Immunovia AB (publ) | 1.57 Million SEK | -20962.222% |
| Prostatype Genomics AB (publ) | 1.35 Million SEK | -24363.864% |
| SenzaGen AB | 49.87 Million SEK | -565.189% |
| Spermosens AB | - SEK | -Infinity% |